Showing 5051-5060 of 5554 results for "".
- FDA Approved Eucrisa (Crisaborole) for ADhttps://practicaldermatology.com/news/fda-approved-eucrisa-crisaborole-for-ad/2458344/The U.S. Food and Drug Administration approved Eucrisa (crisaborole) ointment to treat mild-to-moderate eczema in patients two years of age and older. Eucrisa, applied topically twice daily, is a phosphodiesterase 4 (PDE-4) i
- AnaptysBio, Inc.'s IL-33-Blocker Cleared for Phase 2a Trials in AD, Peanut Allergyhttps://practicaldermatology.com/news/anaptysbio-incs-il-33-blocker-cleared-for-phase-2a-trials-in-ad-peanut-allergy/2458347/The United Kingdom Medicines and Healthcare Products Regulatory Agency has green lighted a Phase 2a clinical trial for AnaptysBio, Inc.’s ANB020 for the treatment of adults with moderate-to-severe atopic dermatitis. The United States Food and Drug Ad
- Can Vaseline Protect High-Risk Infants from Eczema? Study Says Yeshttps://practicaldermatology.com/news/can-vaseline-protect-high-risk-infants-from-eczema-study-says-yes/2458353/Applying low-cost moisturizers including petroleum jelly to a baby's skin for the first six months of his or her life is a cost-effective way to prevent eczema, finds a new study published in JAMA Pediatrics. Seven common moisturizers are cost effective in preventing eczema i
- Patient Enrollment Complete in Phase 3 Acne Trials for Minocycline Foam FMX101https://practicaldermatology.com/news/patient-enrollment-complete-in-phase-3-acne-trials-for-minocycline-foam-fmx101/2458357/Patient enrollment is now complete for two Phase 3 clinical trials evaluating the efficacy and safety of FMX101, a topical 4 percent minocycline foam for the treatment of moderate-to-severe acne, according to Foamix Pharmaceuticals Ltd. Foamix is con
- Merz On The Move: Reflections On Fiscal Year 2015/16https://practicaldermatology.com/news/merz-on-the-move-reflections-on-fiscal-year-201516/2458365/Merz Pharma’s core business has grown by 8.9 percent from EUR 809.8 million to EUR 881.9 million in fiscal 2015/16, the company reports. The company’s total revenue of EUR 1,092.9 million has declined by 5.5 percent compared to previous year
- Office Job, Stress And Diet May Increase Risk of Adult Acnehttps://practicaldermatology.com/news/office-job-stress-diet-may-increase-risk-of-adult-acne/2458370/Lifestyle factors -- including stress -- may play a role in adult acne development, a new study suggests. Researchers in Italy compared 248 women diagnosed with adult acne to 270 women without acne. They found that adult acne was associated with a personal history of acne in adolesce
- US Attorney Announces Charges Against Two Executives Tied to Philidor Pharmacy Schemehttps://practicaldermatology.com/news/us-attorney-announces-charges-against-two-executives-tied-to-philidor-pharmacy-scheme/2458373/The US Attorney’s Office, Southern District of New York has charged two executives in connection with the Philidor Pharmacy scheme that instigated a stock value plunge at Valeant when it was revealed last year. The US Attorney’s office will hold a press conference today to
- New Day Cream, Gel Oil from Ceravehttps://practicaldermatology.com/news/new-day-cream-gel-oil-from-cerave/2458371/Cerave is expanding their Renewing product line. A new Cerave Skin Renewing Day Cream with Broad Spectrum SPF 30 sunscreen and Skin Renewing Gel Oil now join existing products in this line including Renewing Cream Serum and Renewing Night Cream.
- Mederma To Offer Products for Healthier Hair, Skin and Nailshttps://practicaldermatology.com/news/mederma-to-offer-products-for-healthier-hair-skin-and-nails/2458377/It’s not just scar and stretch mark reduction for Mederma anymore. Perhaps best known for such legacy products as scar gel and cream and stretch mark therapy, Mederma is now rolling out three new product lines for healthier hair, skin and nails.
- FDA Approves Expanded Use Of Enbrel To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-expanded-use-of-enbrel-to-treat-children-with-chronic-moderate-to-severe-plaque-psoriasis/2458383/The FDA has approved the supplemental Biologics License Application (sBLA) for the expanded use of Amgen's Enbrel (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis. The approval is based